Abstract Background: The combination of vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) and programmed cell death protein 1 (PD-1) inhibitors has become a standard first-line treatment for advanced clear cell renal cell carcinoma (ccRCC). However, cardiovascular toxicities associated with this combination require further clinical attention.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Xiaolong A.
Contact Xiaolong A., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack